| Autor: |
Kim, John S., Sun, Yifei, Balte, Pallavi, Cushman, Mary, Boyle, Rebekah, Tracy, Russell P., Styer, Linda M., Bell, Taison D., Anderson, Michaela R., Allen, Norrina B., Schreiner, Pamela J., Bowler, Russell P., Schwartz, David A., Lee, Joyce S., Xanthakis, Vanessa, Doyle, Margaret F., Regan, Elizabeth A., Make, Barry J., Kanaya, Alka M., Wenzel, Sally E. |
| Předmět: |
|
| Zdroj: |
Nature Communications; 2/19/2024, Vol. 15, p1-12, 12p |
| Abstrakt: |
This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination. The antibody response to COVID-19 vaccines varies among individuals. Here the authors find that older age, male sex, smoking, higher BMI, vaccine type, and certain comorbidities are associated with lower anti-S1 antibody levels after COVID-19 vaccinations, indicating that certain groups might benefit from higher frequency or doses of vaccination. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink